Richard T. Maziarz

Oregon Health & Science University — United States

Medicine · Health Sciences

85h-index32.1kcitations725works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(265), Acute Myeloid Leukemia Research(158), CAR-T cell therapy research(155), Acute Lymphoblastic Leukemia research(123), Chronic Myeloid Leukemia Treatments(105)

Publications724 total

Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies
Cytotherapy·2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Journal of Clinical Oncology·2025· 3 citedOpen Access
Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience
Blood·2025Open Access
FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML
Blood·2025
Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide
Blood·2025Open Access
Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models
Blood·2025
Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML
Blood·2025Open Access
Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more
Blood·2025
Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation
Blood·2025Open Access
High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients
Blood·2025
Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium
Blood·2025Open Access
Low adherence to cervical cancer screening guidelines among women survivors after allogeneic hematopoietic cell transplantation: Predictors and practice gaps from a single-center analysis
Blood·2025
Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1
Blood·2025Open Access
Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.
Blood·2025Open Access
Supplemental Figure 8 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
2025Open Access
Supplemental Figure 1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
2025Open Access
Supplemental Figure 4 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
2025Open Access
Supplemental Figure 7 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
2025Open Access
Supplemental Figure 2 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
2025Open Access
Supplemental Figure 9 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
2025Open Access
page 1 of 37Next →

Frequent Co-authors

David G. Maloney(12), Hillard M. Lazarus(11), Barry E. Storer(11), Philip L. McCarthy(10), Michael A. Pulsipher(10), Robert Peter Gale(10), Rainer Storb(10), Brenda M. Sandmaier(10), Edmund K. Waller(9), Michael B. Maris(9), Parameswaran Hari(8), Thomas R. Chauncey(8), Sergio Giralt(7), Daniel J. Weisdorf(7), Mary M. Horowitz(7), Steven M. Devine(7), Christopher Bredeson(7), John F. DiPersio(7), Peter A. McSweeney(7), Mohamed L. Sorror(7)